Signature Equity Partners’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.16K Buy
43
+1
+2% +$196 ﹤0.01% 835
2026
Q1
$8.26K Buy
42
+22
+110% +$4.27K ﹤0.01% 845
2025
Q4
$3.49K Buy
+20
New +$3.64K ﹤0.01% 1091

Other funds holding DGX

Signature Equity Partners's DGX Position: Q2 2026 in Review

Signature Equity Partners increased its Quest Diagnostics (DGX) stake by 2.4% in Q2 2026, buying an estimated $196 and bringing the position to 43 shares worth $9.16K. The position accounts for ﹤0.01% of the portfolio, ranked #835.

Signature Equity Partners first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. 1,105 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Signature Equity Partners held 43 shares of Quest Diagnostics worth $9.16K as of Q2 2026.
  • Signature Equity Partners bought 1 Quest Diagnostics share in Q2 2026, an estimated $196.
  • Quest Diagnostics made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #835 holding.
  • Signature Equity Partners first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • 1,105 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.